Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | BID | P55957 | 1/20 | 0.34 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24293381 | 0.88 | PPOX (0.40) | PPOXBCL2A1MAPTKMT2AALDH1A1 | |
| SCHEMBL24293385 | 0.85 | PPOX (0.38) | PPOXBCL2A1MAPTKMT2AALDH1A1 | |
| SCHEMBL7961485 | 0.85 | PPOX (0.38) | PPOXBCL2A1MAPTKMT2A | |
| SCHEMBL7961482 | 0.85 | PPOX (0.38) | PPOXBCL2A1MAPTKMT2A | |
| SCHEMBL5467830 | 0.84 | MAPT (0.37) | PPOXMAPTKMT2AALDH1A1 | |
| SCHEMBL39177 | 0.84 | MAPT (0.37) | PPOXMAPTKMT2AALDH1A1 | |
| SCHEMBL3676781 | 0.84 | PPOX (0.39) | PPOX | |
| SCHEMBL3676777 | 0.84 | PPOX (0.39) | PPOX | |
| SCHEMBL7164157 | 0.83 | PPOX (0.34) | PPOXBCL2A1MAPT | |
| SCHEMBL7894541 | 0.83 | PPOX (0.34) | PPOXBCL2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365493-A1 | COMPOUNDS AND METHODS | DemAgtech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365493-A1 | COMPOUNDS AND METHODS | DDT, CYP19A1, CYP1A1 | PPOX 464/4885BCL2A1 225/4885MAPT 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.